Sanofi announced a significant decline in its COVID-19 and influenza vaccine sales in the third quarter of 2025, with revenues falling 16.8% to €1.525 billion ($1.7 billion) compared to the same period in 2024. This decrease contributed notably to an overall 7.8% drop in total vaccine sales to €3.4 billion ($3.9 billion) for the quarter.
The dip in vaccine sales is attributed primarily to lower flu vaccination rates in the United States early in the season and intense pricing competition, especially in the German market. Sanofi's CEO Paul Hudson highlighted these factors during the company’s Q3 earnings call, noting that despite a high sales benchmark in 2024, the competitive landscape and "soft" vaccination uptake impacted revenues.
Thomas Triomphe, head of Sanofi’s vaccine division, confirmed a slower-than-usual flu shot uptake in the U.S., which contributed to lagging vaccine performance. Despite these challenges, Sanofi reported retaining a strong market share in its vaccine portfolios. The company continues to invest in vaccine innovation, including combination influenza vaccines aimed at improving patient protection.
Complementing the vaccine segment, Sanofi's blockbuster anti-inflammatory drug Dupixent posted a 26.2% sales increase, helping the company offset vaccine revenue declines. Sanofi’s broader strategic focus includes expanding newer drug launches while navigating the fluctuating vaccine market landscape shaped by changing public health dynamics and regulatory policies.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!